NMDA receptor pathways as drug targets

@article{Kemp2002NMDARP,
  title={NMDA receptor pathways as drug targets},
  author={J. Kemp and R. Mckernan},
  journal={Nature Neuroscience},
  year={2002},
  volume={5 Suppl 1},
  pages={1039-1042}
}
Since the mid 1980s, there has been a great deal of enthusiasm within both academia and industry about the therapeutic potential of drugs targeting the NMDA subtype of glutamate receptors. That early promise is just beginning to translate into approvable drugs. Here we review the reasons for this slow progress and critically assess the future prospects for drugs that act on NMDA receptor pathways, including potential treatments for some major disorders such as stroke and Alzheimer's disease… Expand
Paradigm shift in neuroprotection by NMDA receptor blockade: Memantine and beyond
  • S. Lipton
  • Chemistry, Medicine
  • Nature Reviews Drug Discovery
  • 2006
TLDR
The molecular basis for memantine efficacy in neurological diseases that are mediated, at least in part, by overactivation of NMDARs, producing excessive Ca2+ influx through the receptor's associated ion channel and consequent free-radical formation is reviewed. Expand
NMDA receptor subtypes: Structure, function and therapeutics
TLDR
Multiple subtypes of the NMDA receptor comprising distinct subunit combinations exist which subserve distinct roles in the brain and spinal cord, which offers new hope to develop, in a rationale fashion, subtype-targetted therapeutic agents. Expand
Amide-containing NR2B/NMDA receptor antagonists
Discovery of the NR2A-D subtypes of the NMDA receptor and of an allosteric binding site on the NR2B receptor subunit has renewed interest in the therapeutic potential of NMDA receptor antagonists forExpand
Glutamate-based therapeutic approaches: NR2B receptor antagonists.
  • K. Gogas
  • Medicine
  • Current opinion in pharmacology
  • 2006
TLDR
Anatomical, biochemical and pharmacological studies over the past five years have greatly added to the understanding of the role of NR2B subunit-containing NMDA receptors in chronic and neuropathic pain states, and have shown thatNR2B-mediated analgesic effects might be supra- rather than intra-spinally mediated, and that phosphorylation of the NR2 B subunit could be responsible for the initiation and maintenance of the central sensitization seen in neuropathicPain states. Expand
Paradigm shift in NMDA receptor antagonist drug development: molecular mechanism of uncompetitive inhibition by memantine in the treatment of Alzheimer's disease and other neurologic disorders.
  • S. Lipton
  • Psychology, Medicine
  • Journal of Alzheimer's disease : JAD
  • 2004
TLDR
Clinical use has corroborated the prediction that memantine is thus well tolerated and a series of second-generation memantine derivatives are currently in development and may prove to have even greater neuroprotective properties than memantine. Expand
Mechanism-based targeting of NMDA receptor functions
  • G. Popescu
  • Biology, Medicine
  • Cellular and Molecular Life Sciences CMLS
  • 2005
Abstract.NMDA receptors (NRs) are key signaling proteins in the central nervous system and represent important targets for drug development in several neurologic disorders. They are criticallyExpand
Review Mechanism-based targeting of NMDA receptor functions
NMDA receptors (NRs) are key signaling proteins in the central nervous system and represent important targets for drug development in several neurologic disorders. They are critically involved withExpand
Pathologically activated therapeutics for neuroprotection
  • S. Lipton
  • Medicine
  • Nature Reviews Neuroscience
  • 2007
TLDR
This article describes a series of strategies for the development of neuroprotective therapeutics that are both effective and well tolerated, based on the principle that drugs should be activated by the pathological state that they are intended to inhibit. Expand
Insights into structure-activity relationships and CNS therapeutic applications of NR2B selective antagonists.
TLDR
The improved therapeutic index of these compounds is expected to be the result of the subtype selectivity and cellular location of the NR2B receptors within the CNS. Expand
Clinically Tolerated Strategies for NMDA Receptor Antagonism
TLDR
This chapter reviews the logical process that was applied over the last decade to develop memantine as the first clinically tolerated yet effective agent against NMDAR-mediated neurotoxicity. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 44 REFERENCES
NMDA receptor antagonists as analgesics: focus on the NR2B subtype.
Ifenprodil and a group of related compounds are selective antagonists of NR2B-containing NMDA receptors. These compounds are antinociceptive in a variety of preclinical pain models and have a muchExpand
NMDA agonists and antagonists as probes of glutamatergic dysfunction and pharmacotherapies in neuropsychiatric disorders.
TLDR
This review will examine pathophysiological and therapeutic hypotheses generated or supported by clinical studies employing NMDA antagonists and glycine-B agonists and partial agonists, and consider ethical issues related to human psychopharmacological studies employing glutamatergic probes. Expand
Glycine-site antagonists and stroke.
TLDR
This review focuses on the strychnine insensitive glycine binding site located on the NMDA receptor channel, and on the possible use of selective antagonists for the treatment of stroke. Expand
Glutamatergic mechanisms in schizophrenia.
TLDR
Clinical trials indicate agents that enhance NMDA receptor function via the glycine modulatory site reduce negative and variably improve cognitive function in schizophrenics receiving typical antipsychotic medications. Expand
NMDA receptors as targets for drug action in neuropathic pain.
  • C. Parsons
  • Medicine
  • European journal of pharmacology
  • 2001
TLDR
Peripheral NMDA receptors offer a very attractive target for NMDA receptor antagonists that do not cross the blood brain barrier in inflammatory and visceral pain and such agents might be predicted to be devoid of CNS side effects at doses producing powerful antinociception at peripheralNMDA receptors. Expand
Role of NMDA receptors and MAP kinase in the amygdala in extinction of fear: clinical implications for exposure therapy *
  • Michael Davis
  • Psychology, Medicine
  • The European journal of neuroscience
  • 2002
TLDR
Therapeutic interventions based on extinction procedures are commonly used to treat fear disorders, and d‐cycloserine is a widely available and safe compound, which might be usefully combined with traditional extinction‐based approaches in the treatment of clinical fear. Expand
Antiparkinsonian and antidyskinetic activity of drugs targeting central glutamatergic mechanisms
TLDR
It appears that the denervation or intermittent stimulation of striatal dopaminergic receptors differentially activates signal transduction pathways in medium spiny neurons, which modify the phosphorylation state of ionotropic glutamate receptors and consequently their sensitivity to cortical input. Expand
D-serine added to antipsychotics for the treatment of schizophrenia
TLDR
A significant improvement in patients who received D-serine treatment revealed significant improvements in their positive, negative, and cognitive symptoms as well as some performance in Wisconsin Card Sorting Test (WCST). Expand
Schizophrenia and glutamatergic transmission.
  • C. Tamminga
  • Medicine
  • Critical reviews in neurobiology
  • 1998
TLDR
A "working" glutamate hypothesis of schizophrenia is proposed which postulates a diminished glutamatergic transmission in the hippocampal glutamate-mediated efferent pathways and cerebral dysfunction in the hippocampus and its target areas, especially the anterior cingulate cortex. Expand
Glycine antagonist in neuroprotection for patients with acute stroke: GAIN Americas: a randomized controlled trial.
TLDR
Gavestinel administered up to 6 hours after an acute ischemic stroke did not improve functional outcome at 3 months and no statistically significant difference in 3-month survival was observed using Kaplan-Meier curves. Expand
...
1
2
3
4
5
...